| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Recent advancements in biopharmaceutical innovation, particularly with the introduction of BRINSUPRI, underscore a robust pipeline of targeted therapies aimed at serious health conditions. Insmed's strong performance in product development is further reinforced by successful phase III ASPEN and phase II WILLOW clinical trial results for its lung disease treatment. These achievements highlight the company's commitment to addressing unmet medical needs through effective therapies. Overall, the focus on innovation and successful drug development positions Insmed favorably in the biopharmaceutical landscape. |
| The price action of Insmed (INSM) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 1 is bullish. The market sentiment at 1 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.INSM is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 1, and the negative at 0 on 2025-11-19. The forces of Sentiment towards Fundamentals (3.4), Market Risk Appetite (1), Sector Price Trend (1), Stock Price Trend (1), Valuation Sentiment (0.3), Option Sentiment (0), and Price Level Sentiment (0) will drive up the price. The forces of and Price Level Sentiment (0) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| INSM | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-19 | 0%(0%) | 1 | 0.25% | 1 | 3.4 | -1 | |||||||
| 2025-11-18 | 0%(0%) | 1 | 0.25% | 1.2 | 2.9 | -1 | |||||||
| 2025-11-17 | 0%(0%) | 1 | 0.25% | 1.3 | 2.2 | -1 | |||||||
| 2025-11-16 | 0%(0%) | 1 | 0.25% | 1.2 | 2.2 | -1 | |||||||
| 2025-11-15 | 0%(0%) | 1 | 0.25% | 1.2 | 2.6 | -1 | |||||||
| 2025-11-14 | 0%(0%) | 1 | 0.25% | 1.2 | 2.6 | -1 | |||||||
| 2025-11-13 | 0%(0%) | 1 | 0.25% | 1.2 | 2.9 | -1 | |||||||
| 2025-11-12 | 0%(0%) | 1 | 0.25% | 1 | 1 | -1 | |||||||
| 2025-11-11 | 0%(0%) | 1 | 0.25% | 0.8 | 1.9 | -1 | |||||||
| 2025-11-10 | 0%(0%) | 1 | 0.25% | 0.7 | 2.4 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-19 17:08:37 The approval of Brinsupri opens new market opportunities for Insmed, potentially providing a competitive edge in the lung disease treatment sector. |
| 2025-11-19 17:08:37 Insmed's new drug represents an innovation in treatments for non-cystic fibrosis bronchiectasis, indicating a growing trend in specialized healthcare solutions. |
| 2025-11-19 17:08:37 The rise in Insmed's stock price following the EU's approval signals positive investor sentiment and confidence in the company's future. |
| 2025-11-19 17:08:37 The successful phase III ASPEN and phase II WILLOW results highlight Insmed's effective development of its lung disease drug. |
| 2025-11-19 17:08:37 The approval of Brinsupri by the EU is a significant regulatory win for Insmed, indicating strong validation for its treatment. |